Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

William Maguire

Internal Medicine Charleston, SC Medical Doctor

NPI 1528061397 CMS profile 204894

615 Wesley Dr, Suite 300, Charleston, SC 29407

Open in the dashboard

General payments

$6,351

339 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, William Maguire of Charleston, SC is reported in the CMS Open Payments database as having received $6,351 across 339 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,025 49
2024 General $954 49
2023 General $1,088 51
2022 General $1,077 61
2021 General $1,115 61
2020 General $523 32
2019 General $569 36

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • William Maguire
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to William Maguire were reported at $1,025. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year William Maguire Internal Medicine median Middle half National median
2019 $569 $159 $48–$570 $163
2020 $523 $119 $33–$402 $114
2021 $1,115 $135 $37–$521 $132
2022 $1,077 $141 $42–$496 $149
2023 $1,088 $149 $45–$519 $160
2024 $954 $154 $47–$537 $164
2025 $1,025 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $566 34 payments
  2. Lilly USA, LLC $563 27 payments
  3. AbbVie, Inc. $425 25 payments
  4. Pfizer Inc. $379 20 payments
  5. Novo Nordisk Inc $363 21 payments
  6. Exact Sciences Corporation $338 16 payments
  7. GlaxoSmithKline, LLC. $319 17 payments
  8. Salix Pharmaceuticals, a division of Bausch Health US, LLC $284 17 payments
  9. Astellas Pharma US Inc $223 8 payments
  10. Bayer HealthCare Pharmaceuticals Inc. $217 12 payments
  11. Other $2,674 142 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,251 338 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. MOUNJARO $424 20 payments
  2. XIFAXAN $284 17 payments
  3. Cologuard Collection Kit $277 13 payments
  4. EVENITY $255 15 payments
  5. Prolia $255 15 payments
  6. Repatha $246 15 payments
  7. Ozempic $225 13 payments
  8. Kerendia $217 12 payments
  9. RYBELSUS $187 11 payments
  10. UBRELVY $185 12 payments
  11. Other $5,743 317 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 180 drugs

Part D claims

13,210

Median for Internal Medicine: 777

Drug cost

$898,592

Median for Internal Medicine: $73,373

Branded share of claims

22.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 131 $147,762
Jardiance Empagliflozin Brand 118 $131,775
Eliquis Apixaban Brand 124 $124,509
Januvia Sitagliptin Phosphate Brand 90 $88,886
Trulicity Dulaglutide Brand 31 $36,268
Xarelto Rivaroxaban Brand 27 $23,147
Linzess Linaclotide Brand 32 $20,989
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $19,027
Rybelsus Semaglutide Brand 16 $17,899
Myrbetriq Mirabegron Brand 29 $17,264

The 10 drugs with the highest cost, of 180 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$143,818

Of which drugs: $17,250

Medicare patients

424

Average age 75

Services billed

2,008

184 women, 240 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Diabetes 38%
Arthritis 36%
Ischemic heart disease 22%
Chronic kidney disease 21%
Cancer 15%
Atrial fibrillation 14%
Depression 14%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 88 89 $7,039
Pcv20 vaccine im 90677 Office 22 22 $6,380

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $121
$121 — —
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $65
$65 — —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $49
$49 — —
SPRAVATO
  • Janssen Pharmaceuticals, Inc $45
$45 — —
JARDIANCE
  • Lilly USA, LLC $40
$40 118 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

339 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record